Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

ANCHOR CRC: Triple therapy combo improves ORR in BRAF V600E-mutant mCRC

Elaine Soliven
09 Sep 2020

The combination of encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) improves objective response rate (ORR) in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) in the first-line setting, according to the ANCHOR CRC* trial presented at ESMO GI 2020.

BRAFv600e mutation occurs in 10–15 percent of patients with mCRC and confers a poor prognosis,” according to lead author Dr Axel Grothey from West Cancer, University of Tennessee in Germantown, Tennessee, US. “[Moreover,] recent studies with chemotherapy-based regimens have shown poor outcomes”. [Br J Cancer 2009;101:715-721]

This stage 1 analysis of ANCHOR CRC evaluated 40 patients (mean age 67 years, 61 percent were aged ≥65 years) with centrally confirmed BRAFv600E-mutant mCRC who had no prior treatment with any RAF, MEK, or anti-EGFR inhibitors. Participants received oral ENCO 300 mg QD and BINI 45 mg BID + intravenous CETUX (250 mg/m2 after a first dose of 400 mg/m2) weekly for the first 28 weeks, followed by once every 2 weeks (500 mg/m2). Patients continued treatment until disease progression, unacceptable toxicity, or consent of study withdrawal. [ESMO GI 2020, abstract LBA-5]

At baseline, 78 percent and 51 percent of patients had metastases in ≥2 organs and peritoneal metastasis, respectively. 

As per the investigator’s assessment, a high confirmed ORR was noted in 50 percent (95 percent confidence interval [CI], 34–66) of patients, with 85 percent demonstrating a reduction in tumour size (partial response [50 percent] and stable disease [35 percent]).

The median progression-free survival was 4.9 months (95 percent CI, 4.4–8.1).

The most common grade ≥3 adverse events (AEs) reported were diarrhoea (15 percent), anaemia (12 percent), and acute kidney injury (12 percent). “[Most] AEs were comparable to those observed with the same triple combination in BEACON [CRC]** study,” Grothey noted. [NEJM 2019;381:1632-1643]

“Despite the high risk features of the population enrolled in stage 1, including high proportion of patients ≥65 years old and advanced stage at diagnosis (multiple metastatic sites with frequent peritoneal carcinomatosis), most patients [who received the first-line therapy of ENCO + BINI + CETUX] had tumour regression,” Grothey said. 

“[Therefore,] having reached the minimal number of confirmed responses in stage 1, the futility analysis allowed for enrolment of additional patients in stage 2, [which is still ongoing],” Grothey added.

“The triplet combination was well tolerated and manageable with no unexpected toxicities,” he noted.

 

*ANCHOR CRC: encorAfenib, biNimetinib and Cetuximab in subjects witH previOusly untreated BRAF-mutant ColoRectal Cancer

**BEACON CRC: Study of encorafenib + cetuximab plus or minus binimetinib vs. irinotecan/cetuximab or infusional 5-fluorouracil (5-fu)/folinic acid (fa)/irinotecan (FOLFIRI)/cetuximab with a safety lead-in of encorafenib + binimetinib + cetuximab in patients with BRAF v600E-mutant metastatic colorectal cancer

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.